COFFEE EXTRACTS AS INGREDIENTS OF FOODS, DRUGS, COSMETICS, DIETARY SUPPLEMENTS, AND BIOLOGICS
Embodiments are related to compositions of matter comprising a food, drug, cosmetic, dietary supplement, or biologic product, said product comprised of a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction having a ratio of polyphenols to caffeine of about 20, 10-30 or 40, or greater than 10. In related embodiments, said phytochemical fraction is a retentate of a filtration process of a water suspension of crude caffeine, and wherein said crude caffeine is a product of a green coffee bean decaffeination process. In other related embodiments, said compositions of matter are useful for facilitating neuroprotection, inhibiting COX-2 or stimulating glucose uptake.
1 . A composition of matter comprising a food product, said food product comprised of a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction having a ratio of polyphenols to caffeine of about 20, 10-30 or 40, or greater than 10.
2 . The composition of matter of claim 1 , wherein said phytochemical fraction is a retentate of a filtration process of a water suspension of crude caffeine, and wherein said crude caffeine is a product of a green coffee bean decaffeination process.
3 . A process for producing a food product comprising either supplementing a food with, or supplementing a component of a food with, a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction being that as described in claim 1 , whereby said food product is produced.
4 . A composition of matter comprising a drug product, said drug product comprised of a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction having a ratio of polyphenols to caffeine of about 20, 10-30 or 40, or greater than 10.
5 . The composition of matter of claim 4 , wherein said phytochemical fraction is a retentate of a filtration process of a water suspension of crude caffeine, and wherein said crude caffeine is a product of a green coffee bean decaffeination process.
6 . A process for producing a drug product comprising either supplementing a drug with, or supplementing a component of a drug with, a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction being that as described in claim 4 , whereby said drug product is produced.
7 . A composition of matter comprising a cosmetic product, said cosmetic product comprised of a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction having a ratio of polyphenols to caffeine of about 20, 10-30 or 40, or greater than 10.
8 . The composition of matter of claim 7 , wherein said phytochemical fraction is a retentate of a filtration process of a water suspension of crude caffeine, and wherein said crude caffeine is a product of a green coffee bean decaffeination process.
9 . A process for producing a cosmetic product comprising either supplementing a cosmetic with, or supplementing a component of a cosmetic with, a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction being that as described in claim 7 , whereby said cosmetic product is produced.
10 . A composition of matter comprising a dietary supplement product, said dietary supplement product comprised of a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction having a ratio of polyphenols to caffeine of about 20, 10-30 or 40, or greater than 10.
11 . The composition of matter of claim 10 , wherein said phytochemical fraction is a retentate of a filtration process of a water suspension of crude caffeine, and wherein said crude caffeine is a product of a green coffee bean decaffeination process.
12 . A process for producing a dietary supplement product comprising either supplementing a dietary supplement with, or supplementing a component of a dietary supplement with, a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction being that as described in claim 10 , whereby said dietary supplement product is produced.
13 . A composition of matter comprising a biologic product, said biologic product comprised of a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction having a ratio of polyphenols to caffeine of about 20, 10-30 or 40, or greater than 10.
14 . The composition of matter of claim 13 , wherein said phytochemical fraction is a retentate of a filtration process of a water suspension of crude caffeine, and wherein said crude caffeine is a product of a green coffee bean decaffeination process.
15 . A process for producing a biologic product comprising either supplementing a biologic with, or supplementing a component of a biologic with, a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction being that as described in claim 13 , whereby said biologic product is produced.
16 . A process for facilitating neuroprotection, said process comprising:
a. Identifying a human subject in need of neuroprotection; and
b. Administering an amount of the composition of claim 1 to said subject effective to facilitate neuroprotection.
17 . A process for facilitating neuroprotection, said process comprising:
a. Administering an amount of the composition of claim 1 to a human subject effective to facilitate neuroprotection; and
b. Measuring neuroprotection in said subject.
18 . A process for inhibiting COX-2, said process comprising:
a. Identifying a human subject in need of inhibition of COX-2; and
b. Administering an amount of the composition of claim 1 to said subject effective to inhibit COX-2.
19 . A process for inhibiting COX-2, said process comprising:
a. Administering an amount of the composition of claim 1 to a human subject effective to inhibit COX-2; and
b. Measuring inhibition of COX-2 in said subject.
20 . A process for stimulating glucose uptake, said process comprising:
a. Identifying a human subject in need of stimulation of glucose uptake; and
b. Administering an amount of the composition of claim 1 to said subject effective to stimulate glucose uptake.
21 . A process for stimulating glucose uptake, said process comprising:
a. Administering an amount of the composition of claim 1 to a human subject effective to stimulate glucose uptake; and
b. Measuring stimulation of glucose uptake in said subject.
22 . A process for treating dementia or age related cognitive decline, said process comprising:
a. Identifying a human subject in need of treatment of dementia or age related cognitive decline; and
b. Administering an amount of the composition of claim 1 to said subject effective to treat dementia or age related cognitive decline.
23 . A process for treating dementia or age related cognitive decline, said process comprising:
a. Administering an amount of the composition of claim 1 to a human subject effective to treat dementia or age related cognitive decline; and
b. Measuring treatment of dementia or age related cognitive decline in said subject.
24 . A process for inhibiting inflammation, said process comprising:
a. Identifying a human subject in need of inhibition of inflammation; and
b. Administering an amount of the composition of claim 1 to said subject effective to inhibit inflammation.
25 . A process for inhibiting inflammation, said process comprising:
a. Administering an amount of the composition of claim 1 to a human subject effective to inhibit inflammation; and
b. Measuring inhibition of inflammation in said subject.
26 . A process for treating diabetes mellitus, said process comprising:
a. Identifying a human subject in need of treatment of diabetes mellitus; and
b. Administering an amount of the composition of claim 1 to said subject effective to treat diabetes mellitus.
27 . A process for treating diabetes mellitus, said process comprising:
a. Administering an amount of the composition of claim 1 to a human subject effective to treat diabetes mellitus; and
b. Measuring treatment of diabetes mellitus in said subject.
28 . The process of claim 16 , wherein the identifying step or the measuring step is by neuropsychological testing.
29 . The process of claim 18 , wherein the identifying step or the measuring step is by rheumatology criteria.
30 . The process of claim 20 , wherein the identifying step or the measuring step is by blood glucose concentration.